




Figure 1

A) Experimental Paradigm




Figure 2




Figure 2 continued




Figure 3




Figure 3 continued





Figure 4






Figure 5




Figure 5 continued




Figure 6




Figure 6 continued




Figure 7




Figure 7 continued




Figure 8




Figure 8 continued




Figure 9




Figure 9 continued




Figure 10




Figure 10 continued




Figure 11






Figure 11 continued


A) Experimental paradigm




B) Size distribution



C) Concentration



D) Size



E) 661w health




Figure 12




Figure 13

A) Pre-culture B) Post-culture




Figure 14




Figure 15






Figure 16


D) Retinal function - b-wave



F) Inflammation - IBA-1



C) Retinal function - a-wave



E) Cell death - TUNEL




Figure 16 continued




Figure 17




Figure 17 continued




Figure 17 continued




Figure 18

A) RBC health




Figure 19






Figure 20

A) SOD activity Assay



B) Hemoglobin Assay







Figure 21


A) Experimental paradigm




B) Retinal function (ERG) a-wave



C) Retinal function (ERG) b-wave



D) Retinal morphology



E) ONL thickness




Figure 22






Figure 23

A) Human RBC-EV size distribution



B) Human RBC-EV supplement summary



Donor information: Male, O-, 30-31 years

Figure 24




Figure 25




Figure 26





Figure 26 continued

A) Experimental paradigm



B) Cell toxicity assay




Figure 27




Figure 28





Figure 29

A) PCA RBC vs RBC-EV



B) Cellular compartment RBC-EV




Figure 30

C) EV cargo enriched proteins




Figure 30 continued

D) EV membrane enriched proteins




Figure 30 continued

E) Pathway analysis

i) RBC-EV enriched proteins




Figure 30 continued

ii) RBC enriched proteins




Figure 30 continued

iii) downregulated proteins RBC-EV




Figure 30 continued





Figure 31

C) DE PreTx vs PBS



E) Venn




Figure 31 continued




Figure 31 continued




Figure 32




Figure 32 continued

D) DE PBS vs supplements




Figure 32 continued




Figure 32 continued




Figure 33





Figure 33 continued

A) PBMC viability - control



B) PBMC viability - post LPS stimulation




Figure 34




Figure 35




Figure 35 continued




Figure 35 continued




Figure 35 continued




Figure 36




Figure 36 continued




Figure 37